Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Should You Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped up prior to trading on Thursday . The stock had previously closed at $25.4810, but opened at $27.17. Chugai Pharmaceutical shares last traded at $25.92, with a volume of 4,181 shares changing hands.

Chugai Pharmaceutical Stock Up 1.7%

The firm has a market cap of $85.30 billion, a PE ratio of 32.40 and a beta of 0.64. The firm has a 50-day moving average price of $23.20 and a two-hundred day moving average price of $24.21.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. The business had revenue of $2.26 billion for the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%. Research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.